A comparative study between 2% Sertaconazole vs topical 1% Butenafine in tinea infections of skin

A comparative study to evaluate efficacy, safety and cost effectiveness between to evaluate efficacy, safety and topical 1% Butenafine vs topical 2% Sertaconazole in tinea infections of skin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/06/002714

Enrollment

125

Registered

2012-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Tinea infections of skin

Interventions

Intervention1: 2% Sertaconazole: Topical antifungal agent, to be applied twice a day on the lesion for four weeks. Control Intervention1: 1% Butenafine: topical antifungal agent to be applied twice a

Eligibility

Inclusion criteria

Inclusion criteria: New cases of tinea infections of skin from skin OPD

Exclusion criteria

Exclusion criteria: 1) Follow up cases 2) Pregnant and Lactating women 3) patients having hypersensitivity to one of the antifungal agents used in the study

Design outcomes

Primary

Measure	Time frame
a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)Timepoint: a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)	—

Measure

Time frame

a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)Timepoint: a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)

—

Secondary

Measure	Time frame
1) Clinicomycological correlation 2)Relapse rate asssessment 3)Find out the prevalent species of tinea infectionsTimepoint: one month	—

Countries

India

Contacts

Public ContactSaket J Thaker

NIL

drdimplesmehta@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026